AG
AUPH icon

Advisor Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Advisor Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$7K – 5215
2019
Q1 		$7K Buy
+1,000
New +$6.63K ﹤0.01% 4511
2017
Q4 		– Sell
-500
Closed -$3K – 4947
2017
Q3 		$3K Hold
500
– – ﹤0.01% 4414
2017
Q2 		$3K Hold
500
– – ﹤0.01% 4396
2017
Q1 		$4K Buy
+500
New +$2.31K ﹤0.01% 4182

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group's AUPH Position: Q2 2019 in Review

Advisor Group sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2019, closing a stake of 1,000 shares — an estimated $7K sold.

Advisor Group first reported a position in AUPH in Q1 2017 and held it in 4 quarters. The position peaked at $7K in Q1 2019. 73 funds tracked by Wall St. Rank hold AUPH as of Q2 2019.

  • Advisor Group reported no remaining Aurinia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Advisor Group sold 1,000 Aurinia Pharmaceuticals shares in Q2 2019, an estimated $7K.
  • Advisor Group first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Advisor Group's Aurinia Pharmaceuticals position peaked at $7K in Q1 2019.
  • 73 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.